Clinical TrialMay 4, 2026, 08:03 AM
Lifeward ReWalk Exoskeleton Shows 0% Fracture Rate in Germany Since 2018
AI Summary
Lifeward Ltd. announced new clinical data on its ReWalk Personal Exoskeleton, presented at the ASIA 2026 Annual Scientific Meeting. The data, spanning over a decade, demonstrates a consistently favorable and improving safety profile, with a global lifetime fracture prevalence of just 3% since 2013, declining to 0.3% over the past six years. Notably, zero fractures were reported among 97 German users since 2018, reinforcing confidence in the device and supporting its expanded adoption for spinal cord injury mobility.
Key Highlights
- Global lifetime fracture prevalence for ReWalk Exoskeleton is 3% since 2013.
- Fracture incidence declined to 0.3% globally over the past six years (2020 2025).
- Zero fractures reported among 97 German users since 2018.
- 87% of fracture events occurred between 2014 and 2019, indicating safety improvements.
- German cohort included users aged 22-69, with 3-53 years since injury.